Mesoblast Limited (MSB.AX)
| Previous close | 0.9900 |
| Open | 0.9700 |
| Bid | 1.1000 x 1092600 |
| Ask | 1.1050 x 5097500 |
| Day's range | 0.9550 - 1.1100 |
| 52-week range | 0.2550 - 1.3511 |
| Volume | |
| Avg. volume | 11,038,937 |
| Market cap | 1.255B |
| Beta (5Y monthly) | 2.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.58 |
GlobeNewswireAppendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart FailureNEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. Mesoblast Chief Executive Silviu Itescu said: “We are very pleased with the positive interactions we had last quarter with the FDA, having rec
Simply Wall St.Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
As the Australian market navigates through fluctuating bond yields and anticipates potential interest rate hikes, investors are closely monitoring various economic indicators and corporate activities. Amid these conditions, companies with high insider ownership can be particularly intriguing, as such ownership might align management's interests more closely with those of shareholders, potentially fostering greater resilience and long-term strategic focus during uncertain times.
ZacksMesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
